Injection site reactions from peptides: what's normal vs. a red flag

What did @jess_r80 actually say?

In this video, @jess_r80 documents a frustrating string of injection site reactions she's been experiencing over roughly a week and a half. She shows visible lumps and bruising at multiple sites, notes that glutathione has been "the hardest for me to inject" because it "always gives me a reaction," and mentions that injecting it into her glutes instead of subcutaneously reduced the lump. She also calls out two other compounds by name, describing one as "really spicy" and another as "a little bit" irritating. Her main working hypotheses are that the needle may be too short, or that switching from subcutaneous to intramuscular injection might help. She's troubleshooting in real time, which is both relatable and worth examining closely.

Does the science back this up?

Some of it does, actually. The core observation that injection route affects local tolerability is well-supported, even if her reasoning around why isn't fully fleshed out.

Subcutaneous tissue has lower blood flow and less dispersion capacity than muscle, meaning compounds with high osmolarity or low pH linger longer and cause more local irritation. This is documented in pharmaceutical injection literature. A 2019 review by Usach et al. in the Journal of Pain Research found that subcutaneous injection site reactions are strongly tied to formulation pH, volume, and tonicity rather than just the compound itself. Glutathione solutions, particularly at higher concentrations, can be hyperosmolar, which explains the lump and sting she's experiencing.

The idea that switching to intramuscular injection in the glutes reduced her lump is plausible. Muscle tissue has more robust blood flow and can absorb larger volumes more effectively. However, this is not a blanket fix and comes with its own risk profile, including nerve proximity and injection depth requirements that vary significantly by body composition.

What did they get right and wrong?

Credit where it's due: her instinct to inject slowly, to rotate sites, and to compare routes is reasonable harm-reduction thinking. Slow injection reduces pressure-related tissue trauma, and site rotation prevents cumulative scarring. These are consistent with standard injection technique guidance.

Where she goes wrong, or at least incomplete, is in attributing the reactions primarily to the compound rather than the formulation. The "spiciness" she describes from one compound and the burning from NAD is almost certainly tied to pH and concentration of the reconstituted solution, not an inherent property of the peptide or molecule itself. NAD infusions and injections are well-documented to cause flushing, burning, and discomfort because of rapid receptor activation, not because the compound is harmful at the site.

More concerning is the absence of any discussion about sterility, needle gauge, or whether her reactions might indicate something beyond normal tolerability variation. Persistent lumps lasting over a week can be lipohypertrophy from repeated subcutaneous injections, but they can also signal a sterility issue or an allergic response worth flagging to a prescriber.

What should you actually know?

If you're doing subcutaneous injections and getting lumps that last more than a few days, a few things are worth examining before you change your route entirely.

• Formulation pH matters more than most people realize. A solution outside the 6.0-8.0 pH range will cause localized tissue irritation regardless of the compound. If you're reconstituting peptides yourself, the diluent and concentration affect this directly.
• Injection volume is a frequent culprit. Subcutaneous tissue can typically absorb 1-2 mL per site comfortably. Going above that increases lump likelihood significantly.
• Switching from subcutaneous to intramuscular without guidance is not a trivial decision. IM injections into the glutes require correct anatomical landmark identification to avoid the sciatic nerve. A 2020 paper by Wynaden et al. in Nurse Education in Practice found that incorrect IM injection technique is common even among trained practitioners.
• Persistent injection site lumps lasting more than seven to ten days should be evaluated by a clinician. They can represent lipohypertrophy, granuloma formation, or in rare cases, a localized infection.
• The "spicy" sensation from some compounds, particularly NAD, is a known pharmacological effect and not necessarily a sign of a problem. But burning that persists after injection ends, or that is accompanied by redness and warmth, is different and worth attention.

The broader point is that injection site troubleshooting is genuinely complicated, and social media is a poor substitute for working through it with whoever is managing your protocol.